Aktieanalys

BioInvent: First BI-1206 SC Data - Redeye

{newsItem.title}

Redeye Publicerad: 15 May 08:14

Redeye is optimistic about the new data from lymphoma patients treated with subcutaneous as well as intravenous BI-1206.

Länk till analysen i sin helhet: https://www.redeye.se/research/1007353/bioinvent-first-bi-1206-sc-data?utm_source=finwire&utm_medium=RSS

Nyheter om Bioinvent

Läses av andra just nu

Om aktien Bioinvent

Senaste nytt